Celldex Therapeutics, Inc.
Hedge Funds Holdings
Last updated:
Celldex Therapeutics, Inc.‘s stocks are currently a part of 157 hedge funds’ portfolios, which represents 100% of the total amount of its stocks outstanding. This makes up a total of 49.64M shares of Celldex Therapeutics, Inc.. Compared to the previous quarter, the number grew by 7.13% or 3.30M shares more. As for the holding position changes, 40.76% (64) of current hedge fund investors increased the number of shares held, 30.57% (48) of current holders sold a part of the shares held, and 19.11% (30) closed the holdings completely. 18 hedge funds are new holders of Celldex Therapeutics, Inc. stock in Q1 2022, it is 11.46% of total holders.
Hedge funds holding Celldex Therapeutics (Q2 2017 – Q1 2022)
| Q2 2017 | 127 |
|---|---|
| Q3 2017 | 127 |
| Q4 2017 | 130 |
| Q1 2018 | 127 |
| Q2 2018 | 92 |
| Q3 2018 | 82 |
| Q4 2018 | 70 |
| Q1 2019 | 43 |
| Q2 2019 | 41 |
| Q3 2019 | 41 |
| Q4 2019 | 35 |
| Q1 2020 | 32 |
| Q2 2020 | 66 |
| Q3 2020 | 84 |
| Q4 2020 | 122 |
| Q1 2021 | 110 |
| Q2 2021 | 128 |
| Q3 2021 | 156 |
| Q4 2021 | 172 |
| Q1 2022 | 157 |
Hedge funds changes in Celldex Therapeutics positions (Q2 2017 – Q1 2022)
| Q2 2017 | 13 | 42 | 41 | 17 | 14 |
|---|---|---|---|---|---|
| Q3 2017 | 17 | 45 | 28 | 15 | 22 |
| Q4 2017 | 19 | 46 | 38 | 14 | 13 |
| Q1 2018 | 16 | 39 | 33 | 16 | 23 |
| Q2 2018 | 15 | 21 | 35 | 50 | -29 |
| Q3 2018 | 7 | 18 | 32 | 17 | 8 |
| Q4 2018 | 9 | 16 | 24 | 21 | 0 |
| Q1 2019 | 41 | 0 | 2 | 65 | -65 |
| Q2 2019 | 10 | 12 | 11 | 12 | -4 |
| Q3 2019 | 8 | 10 | 12 | 8 | 3 |
| Q4 2019 | 2 | 9 | 12 | 7 | 5 |
| Q1 2020 | 4 | 9 | 8 | 6 | 5 |
| Q2 2020 | 40 | 12 | 9 | 6 | -1 |
| Q3 2020 | 36 | 23 | 12 | 18 | -5 |
| Q4 2020 | 53 | 30 | 23 | 14 | 2 |
| Q1 2021 | 19 | 38 | 36 | 30 | -13 |
| Q2 2021 | 40 | 32 | 37 | 22 | -3 |
| Q3 2021 | 44 | 53 | 46 | 15 | -2 |
| Q4 2021 | 38 | 59 | 50 | 21 | 4 |
| Q1 2022 | 18 | 64 | 48 | 30 | -3 |
Hedge funds changes in Celldex Therapeutics stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 577,000 | 798,000 |
|---|---|---|
| Q3 2017 | 904,000 | 837,000 |
| Q4 2017 | 867,000 | 1,097,000 |
| Q1 2018 | 1,159,000 | 998,000 |
| Q2 2018 | 25,000 | 74,000 |
| Q3 2018 | 11,000 | 13,000 |
| Q4 2018 | 13,000 | 0 |
| Q1 2019 | 508,000 | 0 |
| Q2 2019 | 201,000 | 141,000 |
| Q3 2019 | 163,000 | 134,000 |
| Q4 2019 | 91,000 | 39,000 |
| Q1 2020 | 220,000 | 57,000 |
| Q2 2020 | 13,159,000 | 4,612,000 |
| Q3 2020 | 11,027,000 | 3,968,000 |
| Q4 2020 | 11,761,000 | 8,516,000 |
| Q1 2021 | 22,448,000 | 16,281,000 |
| Q2 2021 | 33,401,000 | 39,486,000 |
| Q3 2021 | 85,895,000 | 69,912,000 |
| Q4 2021 | 95,080,000 | 43,023,000 |
| Q1 2022 | 72,678,000 | 39,327,000 |